Peacock A, Larance B, Bruno R, Pearson SA, Buckley NA, Farrell M, Degenhardt L. Effectiveness and framing of pharmaceutical opioid abuse-deterrent formulations.
Addiction 2019;
114:404-405. [PMID:
30767388 PMCID:
PMC6656581 DOI:
10.1111/add.14556]
[Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/09/2019] [Accepted: 01/14/2019] [Indexed: 12/17/2022]
Abstract
Abuse-deterrent formulations (ADFs) of pharmaceutical opioids have limited capacity to reduce extra-medical use and harm; their impact is likely restricted to prevention of specific practices among population sub-groups. This debate highlights the importance of viewing ADFs as one component in a range of public health responses. Greater involvement of invested parties (e.g., prescribers, consumers) and reframing terminology will reduce discrimination and stigma.
Collapse